Live
- Sunspots and solar flares can affect Earth’s surface
- Discom staff neglect jungle clearance at poles
- Experts at COP29 urge India to tackle short-lived climate pollutants
- AGP inducts new locomotive
- Visakhapatnam: 31-year-old attacks girl for refusing his love
- MyVoice: Views of our readers 15th November 2024
- NWKRTC embraces digital payments to enhance passenger experience
- Beating plastic pollution,a serious task ahead
- Executive cannot ‘bulldoze’ judiciary: SC
- SC denies pre-arrest bail to Jaynarayan
Glenmark gets FDA nod for anti bacterial drug
Glenmark Pharmaceuticals on Tuesday said it has received tentative approval from the US health regulator for its Lacosamide tablets.
New Delhi: Glenmark Pharmaceuticals on Tuesday said it has received tentative approval from the US health regulator for its Lacosamide tablets.
"Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the USFDA for its Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB, Inc," the company said in a regulatory filing.
Glenmark will market this product upon receiving final approval of its Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg ANDA, it added.
The patent listed in the Orange Book for Vimpat Tablets, 50 mg, 100 mg, 150 mg and 200 mg is scheduled to expire on March 17, 2022, the filing said.
According to IMS Health sales data for the 12-month period ending September 2015, the Vimpat market achieved annual sales of approximately $691 million.
Glenmark's current portfolio consists of 102 products authorised for distribution in the US marketplace and 64 ANDA's pending approval with the USFDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth, it said.
